Sign Up
Ready to replace complexity with clarity?
Answer your real world compliance questions (limited time) and save thousands in legal fees and avoided fines.
Automate Compliance TodayUS states A to Z: marijuana, THCA, delta-8, delta-9, delta-10, HHC
State-by-state mapMost read countries: marijuana, CBD and hemp status
All countries on the globeSubstances: status in every state for each one
Compare all substancesFederal hemp redefinition: P.L. 119-103, div. B, sec. 2019
Nov 12, 2026
Applies only to cannabinoids the plant cannot naturally produce.
Dec 11, 2026
The total-THC test, the 0.4 mg per container cap and the exclusion of converted cannabinoids start.
Latest regulatory actions, updated daily
All regulatory actionsHeadlines and the first four sentences are free. Full write-ups, impact reasoning and the archive are for members.
Member · $99/mo
Every rule change, the day it is made.
The price will rise. Join now and $99 a month stays your rate for life.
Become a memberOr read free: every action opens 30 days after it is published. Sign in with email
By topic
Licensing and permitsPackaging and labelingLab testing and QARetail complianceAdvertising and marketingBanking and paymentsTaxesShipping and logisticsTravel and transportLitigationSOPsFor your role
Regulators and agenciesBrands and operatorsRetailers and smoke shopsCultivatorsProcessorsLawyers and complianceInvestorsConsumers and travelersThe Regulator Brief · newsletter
Every rule change that matters, every Monday.
Free: the Monday brief, and every action 30 days after it is published.
Members: the paid weekly, daily alerts and every write-up.
Read by regulators, operators, lawyers and founders.
Cannabis lawyers
Licensed by state. Listings are not endorsements.
By state
Software and services
Compared by fit, never ranked.
Categories
For companies and firms
Be the listing operators and regulators find.
Software and services
Verified, $49/mo: domain-verified badge, your website link, a quote.
Featured, from $399/mo: labeled Featured in your category, monthly release notes.
Lawyers and firms
Claimed, $75/yr: Claimed badge and your firm's website link.
Featured, $199/mo: labeled Featured on your profile.
Claim your companyClaim a lawyer listingPlacements, flat monthly fee
State and country page sponsorshipsExclusive slot on a legality page and its postsRegulator Brief sponsorshipPresenting sponsor or mid-issue banner, free editionMember brief sponsor slotThe paid weekly, read by members onlyFeatured directory placementLabeled Featured in a software categoryCategory sponsorshipOwn one directory category across the sitePaid guest postsLabeled Paid guest post, sponsored linksWrite and partner
Pitch a paid guest postRead guest postsBecome an affiliateSend a tip or correctionContact the teamWho reads it
Regulators at federal, state and county agencies, plus the operators, lawyers and founders they regulate.
Get the media kitSee open placementsSubstances
US states, map and A to ZCountriesFederal hemp 2026: Nov 12 and Dec 11Compound index, every stateTravelling with cannabis or hempMembers get the daily alert email and every full write-up the morning it is published. Every action is free to read 30 days later.
For your role
All news and analysisGuidesAnalysisFAQsTemplates and SOPsCourt filing recapsNews by state and countrySoftware and services: Verified $49/mo, Featured from $399/mo. Lawyers and firms: Claimed $75/yr, Featured $199/mo. Listings are not endorsements.
Regulatory journalism, not legal advice. How we report

Spain’s Ministry of Health has initiated a substantial regulatory shift with the September 2025 publication of a draft royal decree designed to operationalize medical cannabis under a tightly controlled framework. This long-awaited move positions Spain to join other major European markets with a formal medical cannabis program governed by its central authority, the Agencia Española de Medicamentos y Productos Sanitarios (AEMPS). Below, we break down the decree’s structure, its rollout timeline, who can prescribe and dispense, product forms covered, and the broader implications for businesses and patients.
The draft royal decree was released for public consultation at the end of September 2025. Final approval is expected in early 2026, with implementation likely phased over 6–12 months to allow for licensing, infrastructure, and training for prescribers and pharmacies.
For the latest status and official documents, visit the AEMPS Medical Cannabis section.
The draft decree limits prescription authority almost exclusively to hospital-based specialists and physicians practicing within the national health system (SNS). General practitioners and private-clinic doctors will not be able to prescribe, marking a significant contrast to more liberalized regimes like those in the UK.**
This approach is intended to ensure tight clinical oversight and minimize diversion.
Medical cannabis will be dispensed exclusively through hospital system pharmacies. Unlike Germany or the UK, community pharmacies and private clinics are excluded at launch.
This limits point-of-sale options for patients and establishes a highly centralized distribution chain.
Spain’s policy focuses on standardized master formulas and preparations registered with the AEMPS. The decree specifies:
Learn more about product standards via the Forbes coverage on Spain’s decree.
Licensing for cultivation, production, and wholesale will be strictly regulated by AEMPS.
Stay informed on regulatory amendments and rollout phases at AEMPS and industry associations like Business of Cannabis.
Regulatory requirements are evolving. For detailed compliance support, ongoing license monitoring, and expert industry research, visit CannabisRegulations.ai and streamline your path to Spain’s changing cannabis market.